var data={"title":"Biperiden: International drug information (concise)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Biperiden: International drug information (concise)</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5742?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46201826\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">International Brand Names</span>\n    <ul>\n      <li>Akidin (PH);</li>\n      <li>Akineton (AE, AR, AT, AU, BE, BG, BR, CH, CL, CO, CR, CZ, DE, DK, DO, EC, EE, EG, ES, FI, GB, GR, GT, HN, HR, HU, IE, IS, IT, JO, KW, LB, LT, LU, MX, NI, NL, NO, PA, PE, PH, PL, PT, PY, SE, SI, SK, SV, TW, UA, UY, VE, ZA);</li>\n      <li>Akineton LP (VN);</li>\n      <li>Akineton Retard (AT, CL, CO, CR, CY, DE, DO, EC, ES, FR, GT, HN, LB, MX, NI, PA, PE, PT, SV);</li>\n      <li>Akineton SR (PL);</li>\n      <li>Akineton [inj.] (PL);</li>\n      <li>Apiden (PH);</li>\n      <li>Atol (KR);</li>\n      <li>Benzum 2 (PE);</li>\n      <li>Berofin (AR);</li>\n      <li>Biperin (TW);</li>\n      <li>Bipiden (TW);</li>\n      <li>Dekinet (IL);</li>\n      <li>Desiperiden (DE);</li>\n      <li>Kinex (MX);</li>\n      <li>Tasmolin (JP);</li>\n      <li>Thesis (PY);</li>\n      <li>Tonodil (PY)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46201816\" class=\"list synlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Index Terms</span>\n    <ul>\n      <li>Biperiden Hydrochloride</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46201817\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anti-Parkinson's Agent, Anticholinergic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anticholinergic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46201818\" class=\"block iuse drugH1Div\"><span class=\"drugH1\">Reported Use</span>\n    <p style=\"text-indent:0em;\">Control of extrapyramidal symptoms caused by neuroleptics and other similar medications; adjunctive treatment of all forms of Parkinsonism, especially to control symptoms of rigidity and tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46201819\" class=\"block idos drugH1Div\"><span class=\"drugH1\">Dosage Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: 1 to 16 mg/day (maximum: 16 mg/day) in divided doses administered evenly throughout the day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Controlled release: 4 to 16 mg/day (maximum: 16 mg/day) in divided doses administered evenly throughout the day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children 3 to 15 years: Oral: Immediate release: 1 to 2 mg 1 to 3 times daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46201821\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Product available in various countries; not currently available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46201822\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral, as hydrochloride: 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet Controlled Release, Oral, as hydrochloride: 4 mg</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 106993 Version 4.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"International Brand Names\" href=\"#F46201826\" class=\"outlineLink\">International Brand Names</a></li><li class=\"plainItem\"><a sectionName=\"Index Terms\" href=\"#F46201816\" class=\"outlineLink\">Index Terms</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F46201817\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Reported Use\" href=\"#F46201818\" class=\"outlineLink\">Reported Use</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Range\" href=\"#F46201819\" class=\"outlineLink\">Dosage Range</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46201821\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46201822\" class=\"outlineLink\">Dosage Forms</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_INT/106993|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}